LYMPHOPROLIFERATIVE DISORDERS
Clinical trials for LYMPHOPROLIFERATIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new LYMPHOPROLIFERATIVE DISORDERS trials appear
Sign up with your email to follow new studies for LYMPHOPROLIFERATIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other therapies. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells carrying a protein …
Matched conditions: LYMPHOPROLIFERATIVE DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:05 UTC
-
Engineered immune cells get a navigation system to hunt down lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with certain types of lymphoma that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells, plus a…
Matched conditions: LYMPHOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:05 UTC
-
Could a stem cell swap fix broken immune systems?
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely give people with severe T-cell problems a new, working immune system. About 71 participants aged 4 and older will receive chemotherapy and antibody therapy before the transplant, then be followed for …
Matched conditions: LYMPHOPROLIFERATIVE DISORDERS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:52 UTC
-
New cell therapy targets deadly Epstein-Barr virus complications
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain cancers and post-transplant complications. The goal is to see if the treatment can shrink tumors and improve survival. Particip…
Matched conditions: LYMPHOPROLIFERATIVE DISORDERS
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Massive study seeks root causes of blood cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to uncover the genetic causes of blood and bone marrow cancers by analyzing samples from 5,000 participants. Researchers will look for specific cell abnormalities that drive cancer growth and test whether existing drugs can reverse them. The goal is to develop gen…
Matched conditions: LYMPHOPROLIFERATIVE DISORDERS
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC